尼洛替尼与达沙替尼二线治疗慢性髓系白血病的药物经济学评价...

来自 : www.tumorsci.org/abstra...htm? 发布时间：2021-03-25

参考文献【1】Rosti G, Castagnetti F, Gugliotta G, et al. Excellent out-comes at 3 years with nilotinib 800 mg daily in early chronic phase, Ph+chronic myeloid leukemia (CML):results of a phase 2 GIMEMA CML WP clinical trial[J]. B lood, 2010, 116(3):358-359.

【2】Rosti G,Palandri F,Castagnetti F, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia[J]. Blood, 2009, 114(24):4933-4938.

【3】Cortes JE, Jones D, O\'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia[J]. J Clin Oncol, 2010, 28(3):398-404.

【4】SaglioG, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia[J]. N Engl J Med, 2010, 362(5):2251-2259.

【5】Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia:24-month minimum follow-up of the phase 3 randomised ENESTndtrial[J]. Lancet Oncol, 2011, 12(9):841-851.

【6】Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase:ENESTnd 3-year follow-up[J]. Leukemia, 2012, 26(5):2197-2203.

【7】Timothy P, Saglio HG, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib[J]. Blood, 2014, 123(6):1353-1360.

【8】Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia[J]. N Engl J Med, 2010, 362(24):2260-2270.

【9】Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia:2-year followup from a randomized phase 3 trial (DASISION)[J]. Blood, 2012, 119(5):1123-1129.

【10】Jabbour E, Kantarjian H, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia:3-year follow-up from a randomized phase 3 trial (DASISION)[J]. Blood, 2014, 123(4):494-500.

【11】Radich JP, Kopecky KJ, Kamel-Reid S, et al. A randomized phase Ⅱ trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP):The S0325 Intergroup trail[J]. B lood, 2010, 116(3):6.

【12】Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100mg versus imatinib 400mg in newly diagnosed chronic-phase chronic myeloid leukemia[J]. Blood, 2012, 120(19):3898-3905.

【13】O\'Brien S, Berman E, Borghaei H, et al. NCCN Clinical Practice Guidelines in Oncology:Chronic Myelogenous Leukemia[J]. J Nat l Compr Canc Netw, 2009, 7(9):984-1023.

【14】王雅云, 赵洪国, 崔中光, 等. 达沙替尼、尼洛替尼及伊马替尼治疗新诊断慢性髓系白血病慢性期3年临床观察[J]. 中国实验血液学杂志, 2015, 23(2):356-363.

【15】张丽华. 二代酪氨酸激酶抑制剂治疗慢性粒细胞白血病的初步疗效观察[D]. 福建:福建医科大学, 2013.

【16】Jabbour E, Kantarjian H, O\'Brien S, et al. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure[J]. Blood, 2011, 117(6):1822-1827.

【17】Signorovitch JE, Wu EQ, Betts KA, et al. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia:a matchingadjusted indirect comparison of randomized trials[J]. Curr Med Res Opin, 2011, 27(6):1263-1271.